- Trials with a EudraCT protocol (44)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
44 result(s) found for: Conversion disorder.
Displaying page 1 of 3.
EudraCT Number: 2008-004167-19 | Sponsor Protocol Number: 658321 | Start Date*: 2010-01-11 |
Sponsor Name:GGz Nijmegen | ||
Full Title: The effectiveness of antidepressants and psychological intervention in treating conversion disorder, motor type: a randomized placebo controlled clinical trial. | ||
Medical condition: Conversion disorder, motor type. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2008-002226-11 | Sponsor Protocol Number: SIMaMCI | Start Date*: 2008-10-07 |
Sponsor Name:Charité - Unversitätsmedizin Berlin | ||
Full Title: Randomized Controlled Trial of Simvastatin in Amnestic MCI Patients | ||
Medical condition: Amnestic mild cognitive impairment (MCI) denotes clinical conditions in the border zone between normal cognitive functioning and dementia. The definition of amnestic MCI by Petersen and his co-work... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-001898-90 | Sponsor Protocol Number: Crijns01.12-02-026 | Start Date*: 2012-06-25 |
Sponsor Name:Maastricht University Medical Center | ||
Full Title: Effects of vernakalant and flecainide on atrial contractility in patients with atrial fibrillation | ||
Medical condition: Patients with paroxysmal or persistent atrial fibrillation (AF) reporting at the first heart aid. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-004445-17 | Sponsor Protocol Number: AP30663-2001 | Start Date*: 2021-06-29 | |||||||||||
Sponsor Name:Acesion Pharma ApS | |||||||||||||
Full Title: A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group Study of AP30663 Given Intravenously for Cardioversion in Patients with Atrial Fibrillation | |||||||||||||
Medical condition: Atrial Fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001070-18 | Sponsor Protocol Number: 42603ATT4040 | Start Date*: 2015-04-24 | |||||||||||
Sponsor Name:Janssen-Cilag Taiwan | |||||||||||||
Full Title: The Effective and Tolerable Titration Scheme and Dosage in Children with Attention-deficit hyperactivity disorder Treated with OROS-Methylphenidate | |||||||||||||
Medical condition: Attention Deficit Hyperactivity Disorder | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003079-16 | Sponsor Protocol Number: INS-416 | Start Date*: 2021-02-08 | |||||||||||
Sponsor Name:Insmed Incorporated | |||||||||||||
Full Title: ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen ... | |||||||||||||
Medical condition: Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) FR (Trial now transitioned) DE (Ongoing) AT (Trial now transitioned) HU (Completed) GR (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-004017-33 | Sponsor Protocol Number: 3090X1-4405 | Start Date*: 2008-04-17 | |||||||||||
Sponsor Name:Wyeth Pharmaceuticals France | |||||||||||||
Full Title: Reformulated BeneFIX efficacy and safety after conversion from a pdFIX. | |||||||||||||
Medical condition: Hemophilia B | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002919-33 | Sponsor Protocol Number: 207911 | Start Date*: 2018-03-09 | |||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | |||||||||||||
Full Title: Phase IV, open-label, randomized study to enrol healthy adult volunteers, naïve to any previous meningococcal vaccination or meningococcal disease, aged 18-50 years, to be either vaccinated with GS... | |||||||||||||
Medical condition: Meningitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002225-38 | Sponsor Protocol Number: 331-201-00083 | Start Date*: 2018-02-23 | |||||||||||
Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc. | |||||||||||||
Full Title: A Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects with Bipolar I Disorder | |||||||||||||
Medical condition: Treatment of Manic Episodes Associated with Bipolar I Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) PL (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000144-14 | Sponsor Protocol Number: N01276 | Start Date*: 2008-07-14 | |||||||||||
Sponsor Name:UCB Inc | |||||||||||||
Full Title: An international, double-blind, randomized, multi-center, parallel group, historical-control conversion to monotherapy study to evaluate the efficacy and safety of brivaracetam in subjects (≥ 16 to... | |||||||||||||
Medical condition: Partial onset seizures with or without secondary generalization. | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) CZ (Prematurely Ended) DE (Prematurely Ended) SE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002545-42 | Sponsor Protocol Number: INS-415 | Start Date*: 2021-02-08 | |||||||||||
Sponsor Name:Insmed Incorporated | |||||||||||||
Full Title: ARISE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects with Newly Diagnosed Nontuberculous M... | |||||||||||||
Medical condition: Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) DE (Completed) HU (Completed) AT (Completed) NL (Completed) GR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-009952-18 | Sponsor Protocol Number: P071222 | Start Date*: 2010-01-05 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Intérêt des inhibiteurs de l'enzyme de conversion dans l'atteinte rénale précoce des enfants drépanocytaires : Etude randomisée en double aveugle énalapril versus placebo. | |||||||||||||
Medical condition: Atteinte rénale précoce des enfants drépanocytaires. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-002233-12 | Sponsor Protocol Number: CERL080ADE08 | Start Date*: 2006-04-13 | |||||||||||
Sponsor Name:Novartis Pharma GmbH | |||||||||||||
Full Title: Measurement and Analysis of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Patients with Autoimmune Diseases treated with Mycophenolic Acid | |||||||||||||
Medical condition: patients with autoimmune diseases treated with MPA | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-006170-28 | Sponsor Protocol Number: E2007-G000-307 | Start Date*: 2008-09-15 |
Sponsor Name:Eisai Ltd | ||
Full Title: An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-scalation, Parallel-Group Studies to Evaluate the Efficacy and Safety of E2007 (perampanel) Given as Adjunctive Therapy i... | ||
Medical condition: Epilepsy: refractory partial seizures with or without secondary generalisation | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) ES (Completed) AT (Completed) BE (Completed) PT (Completed) LT (Completed) NL (Completed) HU (Completed) FR (Completed) GB (Completed) SE (Completed) EE (Completed) LV (Completed) DK (Completed) IT (Completed) DE (Completed) FI (Completed) BG (Prematurely Ended) GR (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-000145-58 | Sponsor Protocol Number: N01306 | Start Date*: 2008-07-11 | |||||||||||
Sponsor Name:UCB Pharma S.A. | |||||||||||||
Full Title: An international, double-blind, randomized, multi-center, parallel group, historical-control conversion to monotherapy study to evaluate the efficacy and safety of brivaracetam in subjects (≥ 16 to... | |||||||||||||
Medical condition: Partial onset seizures with or without secondary generalization. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) ES (Completed) HU (Prematurely Ended) FI (Prematurely Ended) FR (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-004022-30 | Sponsor Protocol Number: AKB-6548-CI-0041 | Start Date*: 2022-03-02 | ||||||||||||||||
Sponsor Name:Akebia Therapeutics, Inc. | ||||||||||||||||||
Full Title: A MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ONCE DAILY ORAL VADADUSTAT FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH ANEMIA OF CHRONIC KIDNEY DISEASE AFTER CONVERSION FROM... | ||||||||||||||||||
Medical condition: Anemia of Chronic kidney disease (CKD) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Prematurely Ended) ES (Ongoing) FR (Prematurely Ended) PL (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-018064-95 | Sponsor Protocol Number: S52151 | Start Date*: 2012-06-18 |
Sponsor Name:University of Leuven | ||
Full Title: Amyloid imaging in late life depression | ||
Medical condition: Late life depression | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2008-003333-25 | Sponsor Protocol Number: 804P301 | Start Date*: 2009-09-14 | |||||||||||
Sponsor Name:Supernus Pharmaceuticals, Inc. | |||||||||||||
Full Title: Multicenter, Double-Blind, Randomized, Placebo-Controlled, Three-Arm, Parallel Group Study to Evaluate the Efficacy and Safety of Oxcarbazepine Extended-Release (OXC XR) (1200 and 2400mg/day) as Ad... | |||||||||||||
Medical condition: Treatment of seizures of partial origin in subjects with refractory epilepsy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004454-42 | Sponsor Protocol Number: DIABMIND | Start Date*: 2018-04-27 | |||||||||||||||||||||
Sponsor Name:Vall d'Hebron Research Institute | |||||||||||||||||||||||
Full Title: English A pilot interventional study to arrest the progression of cognitive decline in diabetic patients at high risk of developing Alzheimer's disease by reducing hypoglycemic events. | |||||||||||||||||||||||
Medical condition: Cognitive decline in patients affected with mild cognitive impairment | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002603-15 | Sponsor Protocol Number: GANCMV-2011 | Start Date*: 2011-11-21 | |||||||||||
Sponsor Name:FUNDACION INVESTIGACION HOSPITAL CLINICO DE VALENCIA-INSTITUTO DE INVESTIGACION SANITARIA INCLIVA | |||||||||||||
Full Title: Early treatment with ganciclovir of active infection by cytomegalovirus (CMV) in critically ill patients on mechanical ventilation with severe sepsis or septic shock | |||||||||||||
Medical condition: Active infection with cytomegalovirus (CMV) in critically ill patients on mechanical ventilation with severe sepsis or septic shock | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
